Techno Trends

TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.

New Xolair® Treats Severe Chronic Rhinosinusitis with Nasal Polyps

Novartis has discovered a new Xolair® indication for the treatment of severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for adults. Xolair® (omalizumab), is the first discovered treatment option for CRSwNP which specifically targets and blocks the growth...

A Novel Oral Therapy Discovered to Treat Adult Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Blueprint Medicines Corporation discovered GAVRETO™ for the treatment of adult patients with metastatic Rearranged during Transfection (RET) fusion-positive Non-small Cell Lung Cancer (NSCLC)....

Novel Therapy, Toripalimab, Developed to Treat Nasopharyngeal Carcinoma

Toripalimab, a novel therapy has been discovered for the treatment of nasopharyngeal carcinoma by Junshi Biosciences. Toripalimab, the first anti-PD-1 monoclonal antibody developed for the treatment of Nasopharyngeal carcinoma...

Plinabulin Developed to Prevent Chemotherapy-Induced Neutropenia

BeyondSpring Inc develops breakthrough therapy Plinabulin, for chemotherapy-induced neutropenia indication for patients with cancer. Plinabulin is a first-in-class differentiated immune and stem cell modulator....

Kesimpta® (ofatumumab), The First Self Administrated B-cell Therapy Developed

Novartis develops the first and only self administered B-cell therapy, Kesimpta®, for the treatment of relapsing Multiple sclerosis (MS). Kesimpta® becomes the first new B-cell therapy, which can be self-administered once in a month at home by means of Sensoready® autoinjector pen....

GSK Introduces a New Anti-BCMA (B-cell maturation antigen) Therapy, BLENREP

GlaxoSmithKline plc, introduces BLENREP a first-in-class anti-BCMA (B-cell maturation antigen) therapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior therapies including an anti-CD38 monoclonal antibody...

AXS-12 Novel Therapy Discovered for the Treatment of Narcolepsy

Axsome Therapeutics, Inc discovered AXS-12 novel therapy for the treatment of cataplexy in patients with narcolepsy. AXS-12 is an oral, highly selective and potent norepinephrine reuptake inhibitor. AXS-12, developed for cataplexy highlights its potential and provides meaningful benefit and substantial improvement for patients over currently available treatment...

Rozlytrek® (entrectinib), The First Tumour-Agnostic Therapy Discovered

Rozlytrek® (entrectinib), the first tumour-agnostic therapy discovered for the treatment of patients with NTRK fusion-positive, locally advanced or metastatic solid tumours in adult and paediatric patients who have either progressed following prior therapies or who have no acceptable standard therapies....

AstraZeneca Introduces A Breakthrough Therapy-Tagrisso

AstraZeneca introduced Tagrisso (osimertinib), a breakthrough therapy for the adjuvant treatment of patients with early-stage (IB, II and IIIA) Epidermal Growth Factor Receptor-mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC)....

Merck Discovers Breakthrough Therapy HIF-2α Inhibitor MK-6482

Hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor MK-6482, a novel breakthrough therapy discovered by Merck for the treatment of patients with von Hippel-Lindau (VHL) disease-associated Renal Cell Carcinoma (RCC)....

Pevonedistat Novel Therapy Developed for the Treatment of Patients with HR-MDS

Takeda Pharmaceutical has developed Pevonedistat, a NEDD8-activating enzyme (NAE) inhibitor,a novel treatment for Higher-Risk Myelodysplastic Syndromes (HR-MDS) patients....

TECARTUS™ Discovered for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Kite discovered Tecartus™ (brexucabtageneautoleucel, formerly KTE-X19), a novel Chimeric Antigen Receptor (CAR) T for the treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma (MCL)....

CTP-543 Novel Therapy Introduced for the Treatment of Alopecia Areata

Concert Pharmaceuticals, Inc introduces CTP-543, Oral Janus kinase inhibitor for the treatment of moderate-to-severe alopecia areata in adult patients....

Talaris Therapeutics Develops Novel Cell Therapy FCR001 for the Treatment of Scleroderma

Novel cell therapy FCR001, was developed by Talaris for the treatment of patients with diffuse systemic sclerosis (SSc), a severe form of the rare autoimmune disease scleroderma....

A Breakthrough Therapy Developed for Investigational Prenatal Treatment ER-004 a Rare Genetic Condition

ER-004, a breakthrough therapy for the prenatal treatment of XLHED, a life-threatening rare genetic condition was developed by EspeRare....

Gvoke HypoPen™ First Autoinjector Discovered for Severe Hypoglycemia

Xeris Pharmaceuticals, Inc discovered novel Gvoke HypoPen™ (glucagon injection),which is used for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above....

GIMOTI™, Novel Nasal Spray Developed for Treatment of Gastroparesisin Adults

GIMOTI™ (metoclopramide), novel nasal spray developed by Evoke Pharma, Inc specifically for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis....

Breakthrough Therapy, Crysvita Discovered For Treatment of Tumor-Induced Osteomalacia (TIO)

Crysvita (burosumab-twza) injection the first therapy discovered for the treatment of patients with rare disease, tumor-induced osteomalacia (TIO) corresponding to the age two and older....

Eli Lilly and Company Launched New Rapid Acting Insulin Lyumjev™

Lyumjev™, a new and innovative rapid acting insulin ranging from 100 units/mL and 200 units/mL was launched by Eli Lilly and Company to enhance glycemic control in diabetic patients of type 1 & 2....

A Novel Oral Therapy Discovered to Treat Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)

Insmed discovered Brensocatib for the treatment of adult patients with Non-cystic Fibrosis Bronchiectasis (NCFBE) for reducing exacerbations. Brensocatib is a novel oral, reversible inhibitor of Dipeptidyl Peptidase 1 (DPP1) for the treatment of bronchiectasis and other inflammatory diseases....

Latest Issue
Get instant
access to our latest e-book
Thermo Fisher Scientific - Chromatography Solutions Eppendorf - Discover the Flow Meco - 90 years